296 related articles for article (PubMed ID: 27042004)
21. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
22. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
23. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
[TBL] [Abstract][Full Text] [Related]
25. Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
Brose MS; Smit J; Lin CC; Pitoia F; Fellous M; DeSanctis Y; Schlumberger M; Tori M; Sugitani I
Endocr Relat Cancer; 2017 May; 24(5):237-242. PubMed ID: 28270435
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of lenvatinib in treating thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Pharmacother; 2016 Aug; 17(12):1683-91. PubMed ID: 27398740
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
Marotta V; Ramundo V; Camera L; Del Prete M; Fonti R; Esposito R; Palmieri G; Salvatore M; Vitale M; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2013 May; 78(5):760-7. PubMed ID: 23009688
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib: 10 years after the first pivotal trial.
Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
31. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
Gruber JJ; Colevas AD
Oncologist; 2015 Feb; 20(2):113-26. PubMed ID: 25616432
[TBL] [Abstract][Full Text] [Related]
32. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
Dadu R; Devine C; Hernandez M; Waguespack SG; Busaidy NL; Hu MI; Jimenez C; Habra MA; Sellin RV; Ying AK; Cote GJ; Sherman SI; Cabanillas ME
J Clin Endocrinol Metab; 2014 Jun; 99(6):2086-94. PubMed ID: 24628550
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
[TBL] [Abstract][Full Text] [Related]
34. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
35. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
Hegazi M; Azadi A; Jain D; Redman R; Perez CA
Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
[TBL] [Abstract][Full Text] [Related]
36. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
Brown SR; Hall A; Buckley HL; Flanagan L; Gonzalez de Castro D; Farnell K; Moss L; Gregory R; Newbold K; Du Y; Flux G; Wadsley J
BMC Cancer; 2019 Jun; 19(1):582. PubMed ID: 31200667
[TBL] [Abstract][Full Text] [Related]
37. Response to sorafenib treatment in advanced metastatic thyroid cancer.
Pitoia F
Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):37-41. PubMed ID: 24728162
[TBL] [Abstract][Full Text] [Related]
38. pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
Yarchoan M; Ma C; Troxel AB; Stopenski SJ; Tang W; Cohen AB; Pappas-Paxinos M; Johnson BA; Chen EY; Feldman MD; Brose MS
Horm Cancer; 2016 Jun; 7(3):188-95. PubMed ID: 26994002
[TBL] [Abstract][Full Text] [Related]
39. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
40. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Shen CT; Qiu ZL; Luo QY
Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]